Treats serious or severe infections caused by susceptible strains of…. ANDA 65401, held by Eurofarma. Vancomycin Hydrochloride.
As of Nov 16, 2026, ANDA 65401 (Vancomycin Hydrochloride), held by Eurofarma, was first approved by FDA on Jun 30, 2008, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Vancomycin Hydrochloride for Injection is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 2008 | Original application | Approved | None posted |
| Vancomycin HydrochlorideEQ 500MG BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Rx |
| Vancomycin HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Vancomycin Hydrochloride | Rx |
| Apr 30, 2021 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 19, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 19, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 19, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 26, 2013 | Supplement 4Labeling | Approved | None posted |
| Jun 23, 2009 | Supplement 2Labeling | Approved | None posted |
| Jun 30, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters